You are here

From the Archives | Goldman Sachs Asks ‘Is Curing Patients A Sustainable Business Model?’

http://evergreenedigest.org/sites/default/files/Healthcare%20%26%20Money_0.jpg

Gilead Sciences’ 90 percent cure rate of hepatitis C will reportedly send its sales plunging from $12.5 billion in 2015 to less than $4 billion this year.

http://evergreenedigest.org/sites/default/files/Support%20Independent%20Media_0.jpg   Journalism with real independence and integrity is a rare thing. All reader supported Evergreene Digest relies - exclusively!- on reader donations. Click on the donation button on the right to make a contribution and support our work.



CBS Local, New York, NY

April 12, 2018 | Investment banking giant Goldman Sachs is reportedly asking some very cold questions about the healthcare industry and whether it’s a good business move to cure diseases.

In an April 10 financial report titled “The Genome Revolution,” company analysts allegedly posed the question “is curing patients a sustainable business model?” The report broke down the pros and cons of new gene therapy treatments being worked on by biotech companies. Turning the search for medical remedies into a numbers game, analyst Salveen Richter called potential “one shot cures” a bad business decision that will hurt a company’s bottom line.

Full story …

http://evergreenedigest.org/sites/default/files/Editor%20Comment%20icon_0.jpg

Be sure to pass these articles to friends and kin. A lot depends on this. Please do your part.